# A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

Source: https://onco.cc/trials/nct07390383/  
OnCo record `nct07390383` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Capecitabine, Tislelizumab and Oxaliplatin in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.

## Summary

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] is a phase 2 interventional study registered as NCT07390383 by Nanjing Leads Biolabs Co.,Ltd, with 110 participants planned, started 2026-04-13 and due to reach its primary completion in 2028-05-30. Interventions recorded: LBL-024 for Injection, Capecitabine tablets, Tislelizumab Injection and Oxaliplatin injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07390383
- Phase: 2
- Setting: An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 04]
- Sponsor: Nanjing Leads Biolabs Co.,Ltd
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT07390383: https://clinicaltrials.gov/study/NCT07390383

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct07390383.json